Latest News by Industry
BILLERICA, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS ), a leading medical technology company featuring personalized knee and hip replacement products, recently launched a patient education and awareness campaign in selected U.S. markets to strengthen the importance of patient choice by highlighting the differences between traditional “off-the-shelf” products and truly personalized knee systems that offer clinically proven benefits to patients.
The campaign is currently airing in the Boston, MA and Minneapolis-St. Paul, MN metro areas in an effort to educate future patients about their options when it comes to total knee replacement surgery. Independent surveys and Conformis market research show that most of the growing total knee replacement patient population is unaware of stark differences in knee replacement systems, and simply receives the brand of knee replacement system used most frequently by their surgeon.
Conformis makes fully personalized or patient specific knee systems for each patient using advanced 3D imaging technology, which is designed to produce an implant that matches each patient’s unique anatomy, and is designed to offer multiple benefits to patients and medical facilities that have been demonstrated in peer-reviewed clinical studies:
“The U.S. healthcare system is based on choice, yet many patients don’t know they have a choice when it comes to knee replacement surgery, an operation performed several hundred thousand times each year throughout the nation,” said James Paiva, Vice President of Marketing for Conformis. “The highest probability of success is the combination of a great surgeon with a great implant that matches the patient’s anatomical structure, along with great post-operative physical therapy. Through this awareness campaign, our goal is to highlight how a patient’s choice of implant used during their knee replacement surgery can have a big impact on the level of mobility and quality of life.”
More than 50 peer-reviewed studies and articles published in medical journals indicate that fully personalized implants can reduce total costs to the healthcare system because patients recover more quickly and are less likely to require follow-up corrective (revision) surgeries. In addition, according to the study published in The Journal of Bone & Joint Surgery Reviews (JBJS Reviews)4, patients who had undergone bilateral total knee arthroplasty (TKA) preferred their Conformis fully personalized knee compared to their bilateral off-the-shelf knee at a rate of more than 10 to 1.
The Conformis patient awareness campaign, whose primary television spot is seen here, is currently running in the Greater Boston-Seacoast New Hampshire and Metro Minneapolis-St. Paul markets through March. For more information about Conformis and the company’s fully personalized and made-to-measure knee replacement systems, please visit www.conformis.com.
1Zeh, Alexander; Gehler, Valentina; Gutteck, Natalia; Beckmann, Johannes; Brill, Richard; Wohlrab, David. Superior Clinical Results and Higher Satisfaction after Customized Compared with Conventional TKA. Acta Orthopaedica Belgica: December 2021 – Volume 87 – Issue 4 https://doi.org/10.52628/87.4.10
2Kurtz, William, John Slamin, and Scott Doody. Bone Preservation in a Novel Patient Specific Total Knee Replacement. Reconstructive Review 6.1 (2016): 23-29.
https://www.reconstructivereview.org/ojs/index.php/rr/article/view/133/164
http://dx.doi.org/10.15438/rr.6.1.133
3Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant,NavinFernando MD, Ann Chancellor CCRC, Paul Manner MD, University of Washington, Seattle, WA, 2021 Proceedings of Orthopaedic Research Society, Paper 0980
4Schroeder, Lennart ; Dunaway, Andrew DO2; Dunaway, Daniel MD3A Comparison of Clinical Outcomes and Implant Preference of Patients with Bilateral TKA. JBJS Reviews: February 2022 - Volume 10 - Issue 2- e20.00182 doi: 10.2106/JBJS.RVW.20.00182
About Conformis, Inc.
Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future press releases via e-mail alerts, sign up at ir.conformis.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
INVESTOR CONTACT
ir@conformis.com
781.374.5598
Source: Conformis, Inc.